CHE

Rating neutralTentativeAI MemoPost-earnings T+3

Chemed

As of 2026-07-31/Post-earnings T+3/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-31 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

neutral

Confidence

high

Horizon

—

Key catalyst

Q2 earnings and raised full-year guidance • 2026-07-28

Base target: $545 / p=50% prob

Biggest risk

Roto-Rooter remains weak on profitability, VITAS still has $7.0 million of Medicare Cap billing limitation across four provider numbers, and the stock is already above most available target indications. The RBC update is a single-firm revision; broad post-print estimate changes were not confirmed.

Invalidation

Break below $475 or thesis failure.

What would change my mind?

The Q2 print materially strengthened the operating case: VITAS delivered double-digit revenue growth, stronger admissions and margins, and management raised full-year guidance. The 2026-07-30 Benzinga analyst-ratings page reports that RBC maintained Sector Perform while raising its target from $436 to $548, supportive but not an outright bullish revision.

Research note

Recommendation

neutral

Confidence

high

As of

2026-07-31

Base target

$545

p=50%

Bull target

$590

p=25%

Bear target

$475

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Roto-Rooter remains an offset
VITAS growth and lower Medicare Cap burden
The Q2 print materially strengthened the operating case: VITAS delivered double-digit revenue growth, stronger admissions and margins, and management raised full-year guidance.

BearKey bullets

Analyst revision breadth remains limited and no broad post-earnings estimate consensus was confirmed.
Roto-Rooter adjusted EBITDA and margin may remain pressured.
The share price is above the packet's median analyst target, leaving limited valuation support.

WatchKey bullets

Q2 earnings and raised full-year guidance

Summary

High-level snapshot

Recommendation

neutral

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $545 (p=50%)

Target spread vs base: +8% / -13%

Scenario probabilities

Bull Target: $590 (p=25%)Base Target: $545 (p=50%)Bear Target: $475 (p=25%)

Commentary

The SEC-filed Q2 release provides concrete primary-source confirmation of stronger results and raised guidance. The Benzinga quote page showed CHE at $534.79 at the 2026-07-30 close, down 0.85% that day; this is a post-print observation, but the packet does not establish a clean earnings-day attribution. Analyst reaction is limited to the reported RBC target increase and maintained Sector Perform rating, so the muted price response and thin revision breadth support continued monitoring rather than a higher-conviction rerating thesis.

As of 2026-07-31 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Roto-Rooter remains an offset
VITAS growth and lower Medicare Cap burden

Scenarios

Bull Target (Scenario probability)

$590 / p=25% prob

Base Target (Scenario probability)

$545 / p=50% prob

Bear Target (Scenario probability)

$475 / p=25% prob

Analysis 2026-07-31 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.72

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-07-28
Q2 earnings and raised full-year guidance
Chemed reported Q2 revenue of $673.3 million, adjusted diluted EPS of $6.06, and increased full-year guidance, driven mainly by VITAS outperformance. [#SEC-8K-2026-07-28]
Prob 85.00% • Move 5.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

Roto-Rooter remains an offset
2026-10-29
Roto-Rooter revenue increased 3.3%, but adjusted EBITDA was essentially flat and margin declined 77 basis points, leaving execution and margin recovery as near-term watch items. [#SEC-8K-2026-07-28]
Prob 65% • Move -3% • Priced-in 55%

Long-term Catalysts

Months to a year

VITAS growth and lower Medicare Cap burden
2026-12-31
VITAS admissions rose 9.0%, ADC rose 6.1%, adjusted EBITDA margin expanded 196 basis points, and Medicare Cap billing limitation fell sharply year over year. [#SEC-8K-2026-07-28]
Prob 75% • Move 6% • Priced-in 65%

Risks

Analyst revision breadth remains limited and no broad post-earnings estimate consensus was confirmed.
Roto-Rooter adjusted EBITDA and margin may remain pressured.
The share price is above the packet's median analyst target, leaving limited valuation support.
VITAS remains exposed to Medicare Cap billing limitations and acuity-mix changes.

Peers

Symbol	Summary
ABT	Diversified medtech and diagnostics peer; useful valuation anchor but materially broader and less operationally similar to Chemed.
BSX	Higher-growth procedure-focused medtech peer; useful quality-growth comparison but much larger and more hospital-exposed.
EW	Premium structural-heart peer; relevant for healthcare valuation sentiment but not directly comparable to Chemed's hospice and plumbing mix.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-31

Loading AI feed…

Symbol

Summary

ABT

Diversified medtech and diagnostics peer; useful valuation anchor but materially broader and less operationally similar to Chemed.

BSX

Higher-growth procedure-focused medtech peer; useful quality-growth comparison but much larger and more hospital-exposed.

Premium structural-heart peer; relevant for healthcare valuation sentiment but not directly comparable to Chemed's hospice and plumbing mix.